THE 30-SECOND OVERVIEW
At a glance
AOD-9604 and HGH fragment 176-191 are so closely related that many write-ups treat the names as synonyms. They nearly are, and the near part is worth being precise about, because it is one amino acid, and because AOD-9604 happens to be one of the few peptides in this catalogue with a completed human clinical programme to its name.
Both come from the same region of growth hormone
Human growth hormone is a 191-amino-acid protein with several distinguishable functional regions. Work in the 1990s, much of it from Frank Ng's group at Monash University, localised the lipolytic activity of the molecule, its effect on fat metabolism, to the C-terminal tail: roughly residues 177 through 191.
That finding raised an obvious question: could the tail fragment reproduce the fat-metabolism effects of growth hormone without the rest of the molecule, and therefore without growth hormone's effects on IGF-1, glucose handling and tissue growth? The fragments studied to answer it are what both of these compound names refer to.
HGH fragment 176-191 is the generic name for the synthetic C-terminal fragment as it circulates in the research market. AOD-9604 is a specific, defined molecule from Monash's programme: the 177-191 sequence with a tyrosine added at the N-terminal end, giving a 16-residue peptide. The added tyrosine improved the synthetic molecule's stability and behaviour; AOD stands for Anti-Obesity Drug. So AOD-9604 is best described as the clinically developed, tyrosine-modified version of the same fragment.
The mechanistic claim
The interesting property reported for both is separation of effects. In the animal work, the C-terminal fragment stimulated lipolysis and inhibited lipogenesis, while leaving IGF-1 and blood glucose unaffected. Heffernan and colleagues showed lipid-metabolism effects of AOD-9604 in obese mice, including in beta-3 adrenergic receptor knockouts, and Ng's group published metabolic characterisation of the synthetic domain.
Growth hormone itself cannot make that separation claim. Its metabolic effects come bundled with IGF-1 elevation and glucose effects, which is exactly what the fragment work was designed to avoid. Neither fragment binds the growth hormone receptor in the way the parent hormone does, and neither raises IGF-1 in the published work, which is the entire point of the design.
AOD-9604 is the one with human data
This is the practical difference between the two names. Generic fragment 176-191 has essentially no published human record under that name. AOD-9604 went through a full early-stage clinical programme in the 2000s as an oral anti-obesity candidate, including randomised placebo-controlled studies enrolling several hundred participants.
Two findings from that programme matter for anyone reading the research today. First, safety and tolerability were consistently unremarkable; Stier and colleagues collated the human safety experience in 2013 across the trial programme. Second, the phase 2b obesity trial did not meet its efficacy endpoints, and development for that indication stopped. Both halves belong in an honest summary: a clean human safety record, and a failed efficacy programme for the original indication. Later interest in the compound, including cartilage and metabolic research, builds on that base rather than on approval-grade evidence.
Which name on which product
Because AOD-9604 is the defined clinical molecule, that is the name we use for the AOD-9604 vial. The AOD acetate nasal spray supplies the same peptide as an acetate salt in an intranasal format, and the HGH Fragment 176-191 nasal spray carries the fragment under its generic name. When comparing certificates of analysis or published protocols across vendors, sequence is the thing to check, not the label, since the two names are used loosely across the market.
The takeaway
There is no meaningful mechanistic rivalry between AOD-9604 and HGH fragment 176-191; one is the developed, single-tyrosine-modified form of the other, from the same region of growth hormone. The real difference is evidentiary. AOD-9604 carries a documented human safety programme and an equally documented efficacy failure in obesity, while the generic fragment name carries no human record of its own. Research protocols citing human data are, whether they say so or not, citing AOD-9604.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Ng, F. M., Sun, J., Sharma, L., et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278.
2. Heffernan, M., Summers, R. J., Thorburn, A., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Endocrinology, 142(12), 5182-5189.
3. Stier, H., Vos, E., & Kenley, D. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15.
